Business and Finance News, In Brief
Oral Treprostinil Meets Phase III Endpoint
You may also be interested in...
In Kenneth Frazier's first financial call as CEO, the exec withdrew Merck's long-term earnings guidance, citing healthcare reform costs, European pricing pressure and a late-stage pipeline setback.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker